Search
TG Therapeutics Inc
TGTXAdd to Watchlist
55.210USD
-0.510-0.92%
Market hours （ET）Quotes delayed by 15 min
8.45BMarket Cap
17.25P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.92%
5 Days
+1.49%
1 Month
+45.52%
6 Months
+80.84%
Year to Date
+85.21%
1 Year
+50.35%
Key Figures
55.890Open
56.200High
193.28KVolume
17.25P/E TTM
20.81P/E Dynamic
--Dividend TTM
0.13%Turnover Ratio
55.720Prev. Close
54.500Low
8.21MTurnover
361.47P/E Static
14.49P/B
0.00%Div Yield TTM
42.27%ROA
46.48052wk High
0.27Volume Ratio
23.38MNet Profit
153.09MShares
3.2010EPS TTM
1.68Beta
112.60%ROE
25.28052wk Low
3.05%Amplitude
83.65%Gross Margin
8.45BMarket Cap
17.34Reward/Risk
2.70%Risk Rate
TradingKey Stock Score of TG Therapeutics Inc
Currency: USD Updated: 2026-06-29Key Insights
TG Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 52.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TG Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
TG Therapeutics Inc Highlights
StrengthsRisks
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 163.75% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 616.29M.
Fairly Valued
The company’s latest PE is 17.41, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 122.50M shares, increasing 3.47% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 264.03K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.18.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
52.667
Target Price
-5.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
TG Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
TG Therapeutics Inc Info
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Ticker SymbolTGTX
CompanyTG Therapeutics Inc
CEOWeiss (Michael S)
Websitehttps://www.tgtherapeutics.com/
Related Instruments
-2.95%
-1.83%
-2.13%
-1.42%
-1.79%
-1.02%
-0.55%
-0.78%
-1.35%
-1.56%
-1.56%
-1.97%
-2.42%
-2.21%
-0.12%
0.00%
-0.96%
+0.06%
+0.15%
-0.70%Popular Instruments
52258.700
+105.500 (+0.20%)
30099.400
+391.700 (+1.32%)
7470.800
+38.600 (+0.52%)
15603.000
+152.000 (+0.98%)
70849.000
+375.000 (+0.53%)
6305.700
+49.900 (+0.80%)
70.471
+0.155 (+0.22%)
286.040
+4.300 (+1.53%)
197.970
+3.000 (+1.54%)
4050.120
+34.530 (+0.86%)
FAQs
What is the current price of TG Therapeutics Inc (TGTX)?
The current price of TG Therapeutics Inc (TGTX) is 55.72.
What is the symbol of TG Therapeutics Inc?
The ticker symbol of TG Therapeutics Inc is TGTX.
What is the 52-week high of TG Therapeutics Inc?
The 52-week high of TG Therapeutics Inc is 46.48.
What is the 52-week low of TG Therapeutics Inc?
The 52-week low of TG Therapeutics Inc is 25.28.
What is the market capitalization of TG Therapeutics Inc?
The market capitalization of TG Therapeutics Inc is 8.53B.
Is TG Therapeutics Inc (TGTX) currently rated as Buy, Hold, or Sell?
According to analysts, TG Therapeutics Inc (TGTX) has an overall rating of Buy, with a price target of 52.67.
What is the Earnings Per Share (EPS TTM) of TG Therapeutics Inc (TGTX)?
The Earnings Per Share (EPS TTM) of TG Therapeutics Inc (TGTX) is 3.10.
